Core Insights - AstraZeneca (AZN) and Daiichi Sankyo's FDA acceptance of a supplemental biologics license application (sBLA) for Enhertu aims to expand its label for treating HER2-positive breast cancer [1][7] - The sBLA is based on positive results from the phase III DESTINY-Breast09 study, which showed Enhertu combined with Roche's Perjeta significantly improved progression-free survival (PFS) and objective response rate (ORR) compared to standard treatments [3][4] Group 1: FDA Approval and Study Results - The FDA has granted priority review for the sBLA, reducing the review period by four months, with a final decision expected in Q1 2026 [2] - The DESTINY-Breast09 study demonstrated a median PFS of nearly 41 months for the Enhertu-Perjeta combination, compared to about 27 months for the standard taxane chemotherapy with Herceptin and Perjeta [3][7] - The Enhertu-Perjeta regimen achieved an ORR of 85.1%, surpassing the 78.6% ORR of the standard treatment [4][7] Group 2: Market Potential and Strategic Importance - Enhertu is already approved in over 85 countries for second-line HER2-positive breast cancer treatment and has additional approvals for lung and gastric cancers [5] - Both Enhertu and Datroway are projected to achieve peak annual sales of at least $5 billion, contributing to AstraZeneca's goal of reaching $80 billion in annual revenues by 2030 [10] - The partnership between AstraZeneca and Daiichi Sankyo involves joint development and marketing responsibilities, with Daiichi retaining exclusive rights in Japan [9] Group 3: Competitive Landscape - ADCs are viewed as disruptive innovations in cancer treatment, allowing targeted delivery of cytotoxic drugs to tumors [11] - Daiichi Sankyo is developing several ADCs across various cancers and has a partnership with Merck for additional ADCs, indicating a competitive landscape with significant revenue potential [12] - Pfizer's acquisition of Seagen for $43 billion highlights the growing interest in the ADC space, with multiple ADCs contributing to its revenue [13]

Licensing Deal - Glenmark Pharmaceuticals Ltd announced a licensing deal with Chinese drugmaker Hengrui Pharma for its under-development lung and breast cancer drug, Trastuzumab Rezetecan (SHR-A1811) [1][2] - The deal includes an upfront payment of $18 million, regulatory and commercial milestone payments of up to $1.093 billion, and royalties based on net sales within the licensed territory [1][4] Drug Details - Trastuzumab Rezetecan is a next-generation antibody drug conjugate (ADC) targeting HER2-positive cancers, combining an antibody with a chemotherapy drug to deliver treatment directly to cancer cells [2] - The drug was approved in China in May 2025 for treating adult patients with non-small cell lung cancer that is either inoperable or metastatic [3] Clinical Development - Trastuzumab Rezetecan is currently advancing multiple clinical trials and received Orphan Drug Designation from the US FDA in August 2025 for gastric or gastroesophageal junction adenocarcinoma [3] Market Strategy - Under the licensing agreement, Glenmark can develop and commercialize the drug in emerging markets, excluding major regions like China, the US, Canada, Europe, Japan, Russia, and the CIS [4] - The company aims to expand its oncology pipeline and leadership, focusing on delivering next-generation therapies in underserved markets [5] Recent Collaborations - In May 2024, Glenmark entered an agreement with BeOne to market and distribute cancer medicines Tislelizumab and Zanubrutinib in India [6] - In July 2025, Glenmark's US-based unit licensed a blood cancer drug to AbbVie Inc. for $700 million, marking a significant outlicensing deal for Indian drugmakers [6][7] Financial Performance - Glenmark's share price closed 0.2% higher at ₹2,020.10 on the National Stock Exchange following the announcement of the licensing deal [8]

Group 1 - Merck & Co., Inc. has received Breakthrough Therapy Designation from the FDA for raludotatug deruxtecan, targeting platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers expressing CDH6 after bevacizumab treatment [2][3] - The designation is based on data from a phase 1 trial and the ongoing REJOICE-Ovarian01 phase 2/3 study, aimed at accelerating development for patients with significant unmet needs [3] - Approximately 65% of ovarian cancer patients express CDH6, and up to 80% experience relapse after standard therapies, highlighting the drug's potential impact [3] Group 2 - Merck & Co., Inc. is recognized as one of the best stocks to invest in for financial stability and is involved in developing pharmaceuticals, vaccines, biologics, and animal health products [1][4] - The collaboration between Merck and Daiichi Sankyo marks the second breakthrough designation for their oncology partnership, which began in October 2023 [3]

Core Insights - Pfizer (PFE) and AstraZeneca (AZN) are leading players in the oncology sector, with significant revenue contributions from this area [1][2] - Pfizer's oncology sales account for over 25% of total revenues, growing by 9% in H1 2025, while AstraZeneca's oncology sales represent around 43% of total revenues, increasing by 16% in the same period [1][2][11] - Both companies have robust R&D pipelines that are expected to drive future growth [3] Pfizer Overview - Pfizer's acquisition of Seagen in 2023 has bolstered its oncology position [4] - Non-COVID operational revenues are improving, with key products generating $4.7 billion in H1 2025, a 15% operational increase year-over-year [5] - Pfizer anticipates $7.7 billion in cost savings by the end of 2027 and projects a revenue CAGR of approximately 6% from 2025 to 2030 [6] - Challenges include potential declines in COVID-related sales and significant patent expirations expected between 2026 and 2030, impacting key products [7][8] AstraZeneca Overview - AstraZeneca's portfolio includes several blockbuster drugs, with sales exceeding $1 billion, contributing to strong revenue growth [9] - The company plans to launch 20 new medicines by 2030, targeting $80 billion in total revenues [12] - AstraZeneca's newer drugs are contributing positively to top-line growth in 2025 [10] - Challenges include the impact of Medicare Part D redesign on key drug sales and competition from generics and biosimilars [13][14] Financial Estimates and Performance - Pfizer's 2025 sales and EPS estimates indicate modest growth of 0.3% and 1.0%, respectively, with EPS estimates rising from $3.05 to $3.14 [15] - AstraZeneca's 2025 sales and EPS estimates suggest stronger growth of 8.4% and 11.4%, with EPS estimates increasing from $4.50 to $4.58 [16] - Year-to-date stock performance shows Pfizer declining by 9.0%, while AstraZeneca has increased by 17.6% [18] Valuation and Dividend Yield - AstraZeneca's shares trade at a forward P/E ratio of 15.44, while Pfizer's are at 7.79, indicating a more attractive valuation for Pfizer [19] - Pfizer offers a higher dividend yield of 7.1% compared to AstraZeneca's 2.4% [22] - AstraZeneca has a higher return on equity at 32.8% versus Pfizer's 21.4% [22] Investment Outlook - Both companies are rated with a Zacks Rank 3 (Hold), making it challenging to determine a clear investment preference [23] - AstraZeneca is viewed as a safer investment due to its efficient profitability and clearer growth targets, despite Pfizer's attractive valuation and dividend yield [25]

MADISON, Wis. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #biotech--Immuto Scientific Announces Financing and Daiichi Sankyo Collaboration to Uncover a New Class of Therapeutic Targets with Structural Surfaceomics. ...

Summary of Daiichi Sankyo Update / Briefing on September 17, 2025 Company and Industry Overview - **Company**: Daiichi Sankyo - **Industry**: Oncology, specifically focusing on small cell lung cancer (SCLC) and related therapies Key Points and Arguments 1. **Unmet Medical Need in SCLC**: Small cell lung cancer has a high unmet medical need, particularly in extensive stage small cell lung cancer (ES-SCLC), which accounts for approximately 70% of SCLC cases [1][2] 2. **Recent Drug Approvals**: The field has seen new drug approvals, including lurbinectedin in 2020 and tarlatamab in 2024, alongside traditional chemotherapy agents [2] 3. **IEDxB Program Introduction**: The IEDxB program targets B7-H3, an antigen expressed in many cancers but absent in normal cells, presenting a broad opportunity for development [3] 4. **Phase One Trial Results**: The completed phase one trial of IEDxB showed a robust overall response rate (ORR) of 52% and a progression-free survival (PFS) of 6.9 months, indicating strong efficacy across various tumor types [4][5] 5. **Phase Two Study in ES-SCLC**: The phase two study in relapsed ES-SCLC demonstrated a confirmed response rate of 48.2% and a median duration of response of 5.3 months, with a PFS of 4.9 months and overall survival (OS) of 10.3 months [9][10] 6. **Activity in Brain Metastases**: IEDxB showed a response rate of 46% in patients with brain metastases, which is significant given the challenges of treating such cases [9][10] 7. **Safety Profile**: The safety profile of IEDxB is manageable, with an interstitial lung disease (ILD) rate of 12.7%, primarily low grade [9][10] 8. **Breakthrough Therapy Designation**: IEDxB received breakthrough therapy designation from the FDA, which may expedite the review process and approval timeline [20][54] 9. **Combination Studies**: Ongoing studies are exploring combinations of IEDxB with other therapies, including immune checkpoint inhibitors and bispecific agents, to enhance treatment efficacy [11][12][30] 10. **Competitive Landscape**: IEDxB is positioned favorably against competitors like tarlatamab, with a different mechanism of action and a distinct safety profile, which may influence physician prescribing choices [22][24] Additional Important Content 1. **Patient Demographics**: The study population primarily consisted of male patients, with 28% having brain metastases and 50% receiving IEDxB as first-line therapy [7] 2. **Future Development Plans**: Daiichi Sankyo plans to expand IEDxB's application to other cancers, including prostate and vaginal cancers, and is conducting multiple combination studies to explore its full potential [11][12][28] 3. **Regulatory Strategy**: The company is optimistic about the regulatory submission plans due to the breakthrough designation and the completion of pivotal trials [27][54] 4. **Biomarker Strategy**: Current data suggests that a specific biomarker for B7-H3 may not be necessary in SCLC, as the drug shows activity across a broad patient population [32][33] This summary encapsulates the critical insights from the Daiichi Sankyo briefing, highlighting the company's focus on innovative therapies for small cell lung cancer and its strategic positioning in the oncology market.

WCLC 2025 Highlights DAIICHI SANKYO CO., LTD. September 17th (US)/ 18th (JP), 2025 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are vario ...

Core Insights - Merck and Daiichi Sankyo received FDA Breakthrough Therapy Designation for R-DXd, aimed at treating platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancers expressing CDH6 in patients previously treated with Avastin [1][7][10] Group 1: FDA Breakthrough Therapy Designation - The FDA's Breakthrough Therapy Designation for R-DXd accelerates the development and review process for drugs addressing serious conditions, indicating potential significant improvement over existing treatments [2] - The designation was based on data from the ongoing phase II/III REJOICE-Ovarian01 study and a phase I study, with results expected to be presented at an upcoming medical conference [3][7] Group 2: Merck's Investment and Collaboration - Merck acquired global co-development and co-commercialization rights to R-DXd and two other ADCs from Daiichi Sankyo for a total potential consideration of up to $22 billion, while Daiichi Sankyo retains exclusive rights for development in Japan [5][8] - The collaboration has expanded to include MK-6070, a T-cell engager targeting DLL3, obtained from Harpoon Therapeutics [8] Group 3: ADC Market and Competition - ADCs are viewed as a disruptive innovation in the pharmaceutical industry, enhancing cancer treatment by delivering cytotoxic drugs directly to tumors [11] - Daiichi Sankyo is developing several ADCs across various cancers, including Enhertu, which is approved for multiple indications [12] - Pfizer has entered the ADC market through the acquisition of Seagen for $43 billion, adding four ADCs to its portfolio, which have significantly contributed to its revenues [13][14]

Core Viewpoint - Roche has received CE IVDR approval for two label expansions of its VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx assay, enhancing diagnostic capabilities for HER2-targeted therapies in breast and biliary tract cancers [1][6]. Summary by Relevant Sections HER2 Testing in Breast Cancer - The VENTANA HER2 (4B5) test is the first companion diagnostic approved for identifying HR-positive metastatic breast cancer patients classified as HER2-ultralow, who may be eligible for treatment with ENHERTU® [2]. - Approximately 20-25% of HR-positive, HER2-negative breast cancer patients may fall into the HER2-ultralow category, which is a new classification beyond traditional HER2-positive or negative [3][4]. - The test was utilized in the DESTINY-Breast06 trial, showing significant improvement in progression-free survival for patients with HER2-low and HER2-ultralow metastatic breast cancer when treated with ENHERTU compared to standard chemotherapy [4][6]. Biliary Tract Cancer Diagnostics - The VENTANA HER2 (4B5) test is now also approved to identify biliary tract cancer patients with HER2-positive status, who may be eligible for treatment with Jazz Pharmaceuticals' ZIIHERA® [2][4]. - The incidence and mortality rates of biliary tract cancer have been increasing, with patients often diagnosed at advanced stages and having limited treatment options [4]. Roche's Commitment to Diagnostics - Roche emphasizes the importance of advancing diagnostics to provide personalized treatment options for patients facing challenging cancers, ensuring that clinicians can offer life-altering therapies [3][6]. - The VENTANA HER2 (4B5) assay standardizes immunohistochemistry processes, reducing human error and variability, thus enhancing diagnostic reliability [7].

Group 1: Study Initiation and Objectives - Merck and Daiichi Sankyo have initiated the phase III HERTHENA-Breast04 study to evaluate the investigational HER3-directed ADC, patritumab deruxtecan (HER3-DXd), for treating specific breast cancer patients [1][2] - The study will compare HER3-DXd against an investigator's choice of treatment in patients with unresectable locally advanced or metastatic hormone receptor positive, HER2 negative breast cancer who have progressed after endocrine and CDK4/6 inhibitor therapy [2] - The primary endpoints of the study include progression-free survival and overall survival, while secondary endpoints encompass objective response rate, duration of response, and safety [3] Group 2: Clinical Development and Collaboration - The HERTHENA-Breast04 study is based on promising data from previous studies, including ICARUS-Breast01, where HER3-DXd showed positive responses in metastatic breast cancer patients [3] - Merck has acquired global co-development and co-commercialization rights to two additional ADCs from Daiichi Sankyo for a total potential consideration of up to $22 billion, although Daiichi retains exclusive rights for development in Japan [10] - Merck has also expanded its collaboration with Daiichi to co-develop MK-6070, an investigational T-cell engager targeting DLL3, obtained from Harpoon Therapeutics [11] Group 3: ADC Market and Competition - ADCs are viewed as a disruptive innovation in the pharmaceutical industry, enhancing cancer treatment by using antibodies to deliver cytotoxic drugs directly to tumors [13] - Daiichi Sankyo is actively developing several ADCs across various cancer types, including Enhertu, which is marketed in partnership with AstraZeneca and approved for multiple indications [14] - Pfizer has entered the ADC market through the acquisition of Seagen for $43 billion, adding three ADCs to its portfolio that have significantly contributed to its revenues [15][16]